Complex Combination Therapy: The Evolution Toward Rational Polypharmacy in Lithium-Resistant Bipolar Illness

Bipolar Psychopharmacotherapy: Caring for the Patient

Volumn , Issue , 2006, Pages 135-167

  Post, Robert M ^a   Speer, Andrew M ^a   Leverich, Gabriele S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressant refractory; Attention deficit hyperactivity disorder (ADHD); Comorbid anxiety symptoms; Complex combination therapy; Lithium refractory bipolar illness; Pediatric bipolar illness; Psychomotor retardation

Indexed keywords

EID: 33846034181     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470017953.ch9     Document Type: Chapter

References (129)

1. Aagaard J, Vestergaard . Predictors of outcome in prophylactic lithium treatment: A 2-year prospective study. J Affect Disord 1990; 18: 259-266.
2. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986; 10: 115-125.
3. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617-1622.
4. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: A single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115-119.
5. Baldessarini RJ, Tondo L, Faedda GL, Suppes TR, Floris G, Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996; 57: 441-448.
6. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57: 187-190.
7. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003; 64 Suppl. 5: 44-52.
8. Bauer M. Refractoriness induced by lithium discontinuation despite adequate serum lithium levels (letter). Am J Psychiatry 1994; 151: 1522.
9. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435-440.
10. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18: 444-455.
11. Bauer M, Priebe S, Berghofer A, Bschor T, Kiesslinger U, Whybrow PC. Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. J Affect Disord 2001; 64: 35-42.
12. Bauer M, Berghofer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, Adli M, Baethge C, Muller-Oerlinghausen B. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002; 27: 620-628.
13. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar afective disorder with high-dose thyroxine: An open clinical trial. Neuropsychopharmacology 1994; 10: 183-189.
14. Bean RB, Osler SW. Aphorisms: From His Bedside Teaching and Writings. Springfield, Ill.: Charles C. Thomas Publisher, 1951.
15. Beaudry P, Fontaine R, Chouinard G, Annable L. An open clinical trial of clonazepam in the treatment of patients with recurrent panic attacks. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 589-592.
16. Berghofer A, Muller-Oerlinghausen B. No loss of efficacy after discontinuation and reinstitution of long-term lithium treatment? In: Gallicchio VS, Birch NJ, eds Lithium: Biochemical and Clinical Advances. Cheshire: Weidner Publishing Group, 1996, pp. 39-46.
17. Berlant JL. Topiramate in posttraumatic stress disorder: Preliminary clinical observations. J Clin Psychiatry 2001; 62 Suppl. 17: 60-63.
18. Biederman J, Mick E, Bostic JQ, Prince J, Daly J, Wilens TE, Spencer T, Garcia-Jetton J, Russell R, Wozniak J, Faraone SV. The naturalistic course of pharmacologic treatment of children with maniclike symptoms: A systematic chart review. J Clin Psychiatry 1998; 59: 628-637.
19. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry 1995; 56 Suppl. 3: 25-30.
20. Briley M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 2003; 4: 42-45.
21. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ, Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340: 424-429.
22. Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993; 13: 280-283.
23. Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ. Predictors of response to mood stabilizers. J Clin Psychopharmacol 1996; 16: 24S-31S.
24. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
25. Calabrese JR, Shelton M, Rapport D, Youngstrom E, Shirley E, Elhaj O, Packer K, Bilali S, Findling RL. A 20-month, double-blind, maintenance study of lithium vs. divalproex monotherapy in bipolar I and II disorder accompanied by rapid cycling. Bipolar Disord 2003a; 5: 38-38.
26. Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 2003b; 13 Suppl. 2: 57-66.
27. Calabrese JR, Keck PE, Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360.
28. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. J Clin Psychiatry 1989; 50: 418-423.
29. Cochran SD. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J Consult Clin Psychol 1984; 52: 873-878.
30. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, Corominas J. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-407.
31. Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. J Clin Psychiatry 1992; 53: 16-18.
32. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord 2000; 60: 121-130.
33. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986; 10: 9-13.
34. Coryell W, Solomon D, Leon AC, Akiskal HS, Keller MB, Scheftner WA, Mueller T. Lithium discontinuation and subsequent effectiveness. Am J Psychiatry 1998; 155: 895-898.
35. Craighead WE, Miklowitz DJ. Psychosocial interventions for bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 13: 58-64.
36. Davenport YB, Ebert MH, Adland ML, Goodwin FK. Couples group therapy as an adjunct to lithium maintenance of the manic patient. Am J Orthopsychiatry 1977; 47: 495-502.
37. Deakin JFW. Depression and 5HT. Int Clin Psychopharmacol 1991; 6 Suppl. 3: 23-31.
38. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216-1223.
39. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997a; 58: 470-478.
40. Denicoff KD, Smith-Jackson EE, Bryan AL, Ali SO, Post RM. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997b; 154: 1456-1458.
41. Duffy A, Alda M, Kutcher S, Cavazzoni P, Robertson C, Grof E, Grof P. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry 2002; 63: 1171-1178.
42. Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother 1999; 33: 701-703.
43. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R. Dose-response efficacy of paroxetine in preventing depressive recurrences: A randomized, double-blind study. J Clin Psychiatry 1998; 59: 229-232.
44. Frangou S, Raymont V, Bettany D. The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disord 2002; 4: 378-385.
45. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993; 27: 139-145.
46. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S. Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999; 38: 960-965.
47. Fristad MA, Goldberg-Arnold JS, Gavazzi SM. Multifamily psychoeducation groups (MFPG) for families of children with bipolar disorder. Bipolar Disord 2002; 4: 254-262.
48. Fristad MA, Gavazzi SM, Mackinaw-Koons B. Family psychoeducation: An adjunctive intervention for children with bipolar disorder. Biol Psychiatry 2003; 53: 1000-1008.
49. Frye M, Ketter T, Goldberg J, Antonijevic Z, Calabrese J. Previous episode burden and response to treatment in bipolar I disorder. Bipolar Disord 2003; 5: 48.
50. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61: 9-15.
51. Frye MA, Obrocea G, Ketter TA, Dunn RT, Leverich GS, Luckenbaugh DA, Post RM. Efficacy of lamotrigine versus gabapentin versus placebo in refractory affective disorders: crossovers and combination therapy. Aspects of Affect 2005; 1: 46-49.
52. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489-1493.
53. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635-1640.
54. Goldberg JF, Harrow M, Sands JR. Lithium and the longitudinal course of bipolar illness. Psychiatric Ann 1996a; 26: 651-658.
55. Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull. 1996b; 32: 47-54.
56. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression (letter). Am J Psychiatry 1999; 156: 798.
57. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebocontrolled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J Psychiatry 2004; 161: 564-566.
58. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18: 455-460.
59. Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry 2003; 64 Suppl 5: 53-61.
60. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. Lamotrigine-associated rash: Risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985-991.
61. Hellander M. Pediatric bipolar disorder: the parent advocacy perspective. Biol Psychiatry 2003; 53: 935-937.
62. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677-1685.
63. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
64. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O'Brien CP. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004; 75: 233-240.
65. Keck PE, Jr. New antiepileptics in the treatment of bipolar disorder. Syllabus and Proceedings Summary of the 2001 American Psychiatric Association Meeting, New Orleans, May 5-10, Abstract 34E, 93.
66. Keck PE, Jr, McElroy SL. Aripiprazole: A partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003; 12: 655-662.
67. Keller MB. Paroxetine treatment of major depressive disorder. Psychopharmacology Bulletin 2003; 37: 42-52.
68. Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 1999; 19: 511-532.
69. Koukopoulos A, Reginaldi D, Minnai G, Serra G, Pani L, Johnson FN. The long term prophylaxis of affective disorders. Adv in Biochem Psychopharmacol 1995; 49: 127-147.
70. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, Emslie GJ, Weinberg WA, Rush AJ. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adoles Psychiatry 2000; 39: 713-720.
71. Kowatch RA, Sethuraman G, Hume JH, Kromelis M, Weinberg WA. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry 2003; 53: 978-984.
72. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63: 120-125.
73. Kupka RW, Luckenbaugh DA, Post RM, Suppes T, Altshuler LL, Keck PE, Jr, Frye MA, Denicoff KD, Grunze H, Leverich GS, McElroy SL, Walden J, Nolen WA. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005; 162: 1273-1280.
74. Lam DH, Bright J, Jones S, Hayward P, Schuck N, Chisholm D, Sham P. Cognitive therapy for bipolar illness-A pilot study of relapse prevention. Cog Ther Res 2000; 24: 503-520.
75. Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, Parr-Davis G, Sham P. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60: 145-152.
76. Lange KJ, McInnis MG. Studies of anticipation in bipolar affective disorder. CNS Spect 2002; 7: 196-202.
77. Leverich GS, McElroy SL, Altshuler LL, Frye MA, Grunze H, Keck PE, Jr, Kupka RW, Nolen WA, Suppes T, Walden J, Post RM. The anticonvulsant zonisamide in bipolar illness: clinical response and weight loss. Aspects of Affect 2005; 1: 53-56.
78. Levine J, Chengappa KN, Brar JS, Gershon S, Yablonsky E, Stapf D, Kupfer DJ. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000; 2: 120-130.
79. Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry 1995; 152: 1810-1811.
80. Maj M, Pirozzi R, Magliano L, Bartoli . Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-35.
81. Masand PS, Mago R. Duloxetine for pain symptoms in patients with major depressive disorder. Curr. Psychiatry Rep. 2005; 7: 203-205.
82. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025-1033.
83. McElroy SL, Altshuler LL, Suppes T, Keck PE, Frye MA, Denicoff KD, Nolen WA, Kupka RW, Leverich GS, Rochussen JR, Rush AJ, Post RM. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420-426.
84. McElroy SL, Suppes T, Keck PE, Jr, Black D, Frye MA, Altshuler LL, Nolen WA, Kupka RW, Leverich GS, Walden J, Grunze H, Post RM. Open-label adjunctive zonisamide in the treatment of bipolar disorders: A prospective trial. J Clin Psychiatry 2005; 66: 617-624.
85. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003; 5 Suppl 2: 20-35.
86. Miklowitz DJ. The Bipolar Disorder Survival Guide: What You and Your Family Need to Know. New York: Guilford Press, 2002.
87. Miklowitz DJ, Richards JA, George EL, Frank E, Suddath RL, Powell KB, Sacher JA. Integrated family and individual therapy for bipolar disorder: Results of a treatment development study. J Clin Psychiatry 2003; 64: 182-191.
88. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580-592.
89. Nemeroff CB. Safety of available agents used to treat bipolar disorder: Focus on weight gain. J Clin Psychiatry 2003; 64: 532-539.
90. Ninan PT. Use of venlafaxine in other psychiatric disorders. Depress Anxiety 2000; 12 Suppl. 1: 90-94.
91. Nolen WA, Luckenbaugh DA, Altshuler LL, Suppes TM, McElroy SL, Frye MA, Kupka RW, Keck PE, Leverich GS, Post RM. Correlates of 1 year prospective outcome in bipolar disorder: Results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004; 161:1447-1454.
92. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123-129.
93. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253-260.
94. Otto MW, Reilly-Harrington N, Sachs GS. Psychoeducational and cognitive-behavioral strategies in the management of bipolar disorder. J Affect Disord 2003; 73: 171-181.
95. Palmer A, Tucker S, Swift A. Group mindfulness based cognitive therapy for bipolar disorder. Bipolar Disord 2003; 5: 73.
96. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341-348.
97. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20: 467-471.
98. Passmore MJ, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, Teehan A, Alda M. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003; 5: 110-114.
99. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993; 49: 257-272.
100. Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA, George MS, Kimbrell TA, Leverich GS, Cora-Locatelli G, Luckenbaugh D. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998; 18: 404-413.
101. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br Med J 1999; 318: 149-153.
102. Pollack MH. Innovative uses of benzodiazepines in psychiatry. Can J Psychiatry 1993; 38 Suppl 4: S122-S126.
103. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders (letter). Am J Psychiatry 1998; 155: 992-993.
104. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29-34.
105. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatry Res 1987; 21: 71-83.
106. Post RM, Weiss SRB. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol Neurobiol 1996; 13: 33-60.
107. Post RM, Leverich GS, Altshuler L, Mikalauskas K. Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992; 149: 1727-1729.
108. Post RM, Leverich GS, Pazzaglia PJ, Mikalauskas K, Denicoff K. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MS, eds Lithium in Medicine and Biology. Lancashire, UK: Marius Press, 1993. p. 71-84.
109. Post RM, Speer AM. A brief history of anticonvulsant use in affective disorders. In: Trimble MR, Schmitz B, eds Seizures, Affective Disorders and Anticonvulsant Drugs. Surrey, UK: Clarius Press, 2002a. p. 53-81.
110. Post RM, Speer AM, Obrocea GV, Leverich GS. Acute and prophylactic effects of anticonvulsants in bipolar depression. Clin Neurosci Res 2002b; 2: 228-251.
111. Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck PE, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. J Clin Psychiatry 2003a; 64: 680-690.
112. Post RM, Speer AM, Hough CJ, Xing G. Neurobiology of bipolar illnes: Implications for future study and therapeutics. Ann Clin Psychiatry 2003b; 15: 85-94.
113. Prien RF, Caffey EMJ, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1974; 31: 189-192.
114. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028-1042.
115. Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Prog Neuropsychopharmacol 1981; 5: 507-510.
116. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA, III,. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-113.
117. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157: 229-233.
118. Sonne SC, Brady KT. Substance abuse and bipolar comorbidity. Psychiatr Clin North Am 1999; 22: 609-27, ix.
119. Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations. Arch Gen Psychiatry 1982; 39: 311-312.
120. Strakowski SM, Del Bello MP, Adler CM, Keck PE, Jr. Atypical antipsychotics in the treatment of bipolar disorder. Expert Opin Pharmacother 2003; 4: 751-760.
121. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-1088.
122. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, McElroy SL, Rush AJ, Kupka R, Frye MA, Bickel M, Post RM. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord 2001; 67: 45-59.
123. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264-1266.
124. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
125. Tondo L, Baldessarini RJ, Floris G, Rudas N. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Am J Psychiatry 1997; 154: 548-550.
126. Tramontina S, Schmitz M, Polanczyk G, Rohde LA. Juvenile bipolar disorder in Brazil. clinical and treatment findings. Biol Psychiatry 2003; 53: 1043-1049.
127. Viguera AC. Course of bipolar disorder in pregnancy. Bipolar Disord 2003; 5: 17-18.
128. Weiss SR, Clark M, Rosen JB, Smith MA, Post RM. Contingent tolerance to the anticonvulsant effects of carbamazepine: Relationship to loss of endogenous adaptive mechanisms. Brain Res Brain Res Rev 1995; 20: 305-325.
129. Zarate CA, Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60.